Join
Live feed
·
PRReleasevia Quantisnow
Biomea Fusion Inc. logo

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

ByQuantisnow·Wall Street's wire, on your screen.
BMEA· Biomea Fusion Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMEA (Biomea Fusion Inc.) and more on Quantisnow.